AbbVie (ABBV)
(Delayed Data from NYSE)
$173.61 USD
+1.29 (0.75%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABBV 173.61 +1.29(0.75%)
Will ABBV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABBV
Q2 Earnings in Full Swing This week
First Full Week of Q2 Earnings, PCE Out Friday
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
Other News for ABBV
Johnson & Johnson: Seriously Undervalued At Peak Pessimism
Options Volatility and Implied Earnings Moves This Week, July 22 – July 26, 2024
Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie
Kamala Harris' potential impact on health care stocks
Earnings week ahead: TSLA, GOOG, IBM, AAL, GM, F, VZ, T, and more